By Olivia Bugault

Bayer AG said Wednesday that it has launched a cell and gene therapy platform within its pharmaceutical division in order to speed up innovation.

"The role of Bayer's cell and gene therapy platform is to steer strategically, ensuring the different parts of the organization complement each other and combining the best in Biotech and Pharma know-how," the German chemicals and pharmaceutical conglomerate said.

The platform will complement Bayer's existing pipeline of cell and gene therapy products that comprises five assets and over fifteen preclinical candidates, the company said.

Write to Olivia Bugault at olivia.bugault@wsj.com

(END) Dow Jones Newswires

December 02, 2020 03:26 ET (08:26 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Bayer
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Bayer